Citations

Showing 10 of 108152 citations.

Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus
Binnicker, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | August 4, 2021 | Volume: 59 | Issue: 11 | Pages: No page available

10.1128/jcm.00469-21 | PMID 34346713 Get It

Since the beginning of the COVID-19 pandemic, molecular methods (e.g., real-time PCR) have been the primary means of diagnosing the disease. It is now well-established that molecular tests can continue to detect SARS-CoV-2 genomic RNA for weeks or months following the resolution of clinical illness.
Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies
Keren, David F., Bocsi, Gregary, Billman, Brooke L., Etzell, Joan, Faix, James D., Kumar, Shaji, Lipe, Brea, McCudden, Christopher, Montgomery, Roberta, Murray, David L., Rai, Alex J., Redondo, Teresita Cuyegkeng, Souter, Lesley, Ventura, Christina B., Ansari, Mohammad Qasim, McCudden, Christopher R. , Ansari, M. Qasim , Lipe, Brea , Lipe, Brea , Keren, David F., Bocsi, Gregary, Billman, Brooke L. , Etzell, Joan, Faix, James D., Kumar, Shaji, Montgomery, Roberta, Murray, David L., Rai, Alex J., Redondo, Teresita Cuyegkeng, Souter, Lesley, Ventura, Christina B., Ansari, Mohammad Qasim

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 4, 2021 | Volume: 146 | Issue: 5 | Pages: 575-590

10.5858/arpa.2020-0794-cp | PMID 34347866 Get It

Context.— The process for identifying patients with monoclonal gammopathies is complex. Initial detection of a monoclonal immunoglobulin protein (M protein) in the serum or urine often requires compilation of analytical data from several areas of the laboratory. The detection of M proteins depends on adequacy of the sample provided, available clinical information, and the laboratory tests used. Objective.— To develop an evidence-based guideline for the initial laboratory detection of M proteins. Design.— To develop evidence-based recommendations, the College of American Pathologists convened a panel of experts in the diagnosis and treatment of monoclonal gammopathies and the laboratory procedures used for the initial detection of M proteins. The panel conducted a systematic literature review to address key questions. Using the Grading of Recommendations Assessment, Development, and Evaluation approach, recommendations were created based on the available evidence, strength of that evidence, and key judgements as defined in the Grading of Recommendations Assessment, Development, and Evaluation Evidence to Decision framework. Results.— Nine guideline statements were established to optimize sample selection and testing for the initial detection and quantitative measurement of M proteins used to diagnose monoclonal gammopathies. Conclusions.— This guideline was constructed to harmonize and strengthen the initial detection of an M protein in patients displaying symptoms or laboratory features of a monoclonal gammopathy. It endorses more comprehensive initial testing when there is suspicion of amyloid light chain amyloidosis or neuropathies, such as POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome, associated with an M protein.
Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine
Tailor, Prashant D. , Feighery, Aoife M. , El‐Sabawi, Bassim , Tailor, Prashant D , Prasad, Abhiram

Mayo Clinic

European Heart Journal - Case Reports | August 4, 2021 | Volume: 5 | Issue: 8 | Pages: No page available

10.1093/ehjcr/ytab319 | PMID 34514306 Get It

Abstract Background The SARS-CoV-2 pandemic has led to the development of the first mRNA vaccines used in humans. The vaccines are well tolerated, safe, and highly efficacious; however, post-marketing surveillance is revealing potential rare adverse effects. We report a case of symptomatic acute myocarditis following administration of the second dose of mRNA-1273 SARS-CoV-2 vaccine. Case summary A 44-year-old man presented with chest pain and ST-segment elevation 4 days after receiving the second dose of mRNA-1273 SARS-CoV-2 Vaccine. Emergent coronary angiogram showed minimal coronary artery disease. Cardiac magnetic resonance imaging confirmed acute myocarditis. Diagnosis of vaccine-associated myocarditis was made given the temporal relationship and supportive treatment initiated. Follow-up at 1 month confirmed complete symptomatic recovery and echocardiogram demonstrated normalization of cardiac function. Discussion Acute myocarditis should be considered in patients who present with chest pain or dyspnoea within days of receiving mRNA-1273 SARS-CoV-2 vaccination, especially after the second dose. This may be managed successfully with supportive therapies with complete recovery of cardiac function and symptoms. Further research is warranted to determine the mechanisms by which mRNA vaccines may cause myocarditis and for potential long-term cardiovascular injury.
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
McCoy, Rozalina G. , Houten, Holly K. Van , Karaca‐Mandic, Pinar , Montori, Víctor M. , Shah, Nilay D. , Montori, Victor M , McCoy, Rozalina Grubina , Ross, Joseph S.

Mayo Clinic

Diabetes Care | August 4, 2021 | Volume: 44 | Issue: 10 | Pages: 2302-2311

10.2337/dc20-2977 | PMID 34348996 Get It

OBJECTIVE To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among patients with cardiovascular disease, heart failure (HF), or nephropathy, where these drug classes have established benefit, compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), for which corresponding benefits have not been demonstrated. RESEARCH DESIGN AND METHODS We retrospectively analyzed claims of adults with type 2 diabetes included in OptumLabs Data Warehouse, a deidentified database of commercially insured and Medicare Advantage beneficiaries, who first started GLP-1RA, SGLT2i, or DPP-4i therapy between 2016 and 2019. Using multinomial logistic regression, we examined the relative risk ratios (RRR) of starting GLP-1RA and SGLT2i compared with DPP-4i for those with a history of myocardial infarction (MI), cerebrovascular disease, HF, and nephropathy after adjusting for demographic and other clinical factors. RESULTS We identified 75,395 patients who started GLP-1RA, 58,234 who started SGLT2i, and 91,884 who started DPP-4i. Patients with prior MI, cerebrovascular disease, or nephropathy were less likely to start GLP-1RA rather than DPP-4i compared with patients without these conditions (RRR 0.83 [95% CI 0.78–0.88] for MI, RRR 0.77 [0.74–0.81] for cerebrovascular disease, and RRR 0.87 [0.84–0.91] for nephropathy). Patients with HF or nephropathy were less likely to start SGLT2i (RRR 0.83 [0.80–0.87] for HF and RRR 0.57 [0.55–0.60] for nephropathy). Both medication classes were less likely to be started by non-White and older patients. CONCLUSIONS Patients with cardiovascular disease, HF, and nephropathy, for whom evidence suggests a greater likelihood of benefiting from GLP-1RA and/or SGLT2i therapy, were less likely to start these drugs. Addressing this treatment/benefit paradox, which was most pronounced in non-White and older patients, may help reduce the morbidity associated with these conditions.
Atypical Metastases in the Abdomen and Pelvis From Biochemically Recurrent Prostate Cancer:11C-Choline PET/CT With Multimodality Correlation
Patra, Anurima, Khasawneh, Hala, Suman, Garima, Nathan, Mark A., Packard, Annie T., Johnson, Geoffrey B., Goenka, Ajit H., Johnson, Geoffrey B. , Khasawneh, Hala , Johnson, Geoffrey B , Khasawneh, Hala , Patra, Anurima, Suman, Garima, Nathan, Mark A., Packard, Annie T., Johnson, Geoffrey B., Goenka, Ajit H.

Mayo Clinic

American Journal of Roentgenology | August 4, 2021 | Volume: 218 | Issue: 1 | Pages: 141-150

10.2214/ajr.21.26426 | PMID 34346785 Get It

In Reference to Gender‐Based Pay Discrimination in Otolaryngology
O’Brien, Erin K. , Moore, Eric J. , O'Brien, Erin K

Mayo Clinic

The Laryngoscope | August 4, 2021 | Volume: 131 | Issue: 11 | Pages: No page available

10.1002/lary.29794 | PMID 34347290 Get It

Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches
Narasimhan, Bharat , Narasimhan, Harish , Lorente‐Ros, Marta , Romeo, Francisco José , Bhatia, Kirtipal , Aronow, Wilbert S.

Mayo Clinic

Expert Opinion on Investigational Drugs | August 4, 2021 | Volume: 30 | Issue: 9 | Pages: 947-963

10.1080/13543784.2021.1964471 | PMID 34346802 Get It

Leadership for careful and kind care
Allwood, Dominique , Koka, Sreenivas , Armbruster, Ryan , Armbruster, Ryan, Montori, Víctor M.

Mayo Clinic

BMJ Leader | August 4, 2021 | Volume: 6 | Issue: 2 | Pages: 125-129

10.1136/leader-2021-000451 | PMID 36170535 Get It

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
Khan, Aliya , Rubin, Mishaela R. , Vokes, Tamara , Ahmed, Intekhab, Hofbauer, Lorenz C. , Marcocci, Claudio , Palermo, Andrea , Eriksen, Erik Fink , Brod, Meryl , Markova, Denka, Pihl, Susanne, Mourya, Sanchita, Karpf, David, Shu, Aimee D , Clarke, Bart, Marcocci, Claudio , Palermo, Andrea , Shu, Aimee D , Hofbauer, Lorenz C , Rejnmark, Lars , Schwarz, Peter , Clarke, B.L. , Pagotto, Uberto , Smith, Alden Raymond

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 4, 2021 | Volume: 107 | Issue: 1 | Pages: e372-e385

10.1210/clinem/dgab577 | PMID 34347093 Get It

Abstract Context Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. Objective This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism. Methods This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 µg PTH(1-34)/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 µg PTH[1-34]/day). Results By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D = 0 μg/day and calcium [Ca] ≤ 500 mg/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg/24h to 178 mg/24h by Week 26 (n = 44) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events. Conclusion TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.